Efficacy of the New Neuraminidase Inhibitor CS-8958 against H5N1 Influenza Viruses

English version České info

Currently, two neuraminidase (NA) inhibitors, oseltamivir and zanamivir, which must be administrated twice daily for 5 days for maximum therapeutic effect, are licensed for the treatment of influenza. However, oseltamivir-resistant mutants of seasonal H1N1 and highly pathogenic H5N1 avian influenza A viruses have emerged. Therefore, alternative antiviral agents are needed. Recently, a new neuraminidase inhibitor, R-125489, and its prodrug, CS-8958, have been developed. CS-8958 functions as a long-acting NA inhibitor in vivo (mice) and is efficacious against seasonal influenza strains following a single intranasal dose. Here, we tested the efficacy of this compound against H5N1 influenza viruses, which have spread across several continents and caused epidemics with high morbidity and mortality. We demonstrated that R-125489 interferes with the NA activity of H5N1 viruses, including oseltamivir-resistant and different clade strains. A single dose of CS-8958 (1,500 µg/kg) given to mice 2 h post-infection with H5N1 influenza viruses produced a higher survival rate than did continuous five-day administration of oseltamivir (50 mg/kg twice daily). Virus titers in lungs and brain were substantially lower in infected mice treated with a single dose of CS-8958 than in those treated with the five-day course of oseltamivir. CS-8958 was also highly efficacious against highly pathogenic H5N1 influenza virus and oseltamivir-resistant variants. A single dose of CS-8958 given seven days prior to virus infection also protected mice against H5N1 virus lethal infection. To evaluate the improved efficacy of CS-8958 over oseltamivir, the binding stability of R-125489 to various subtypes of influenza virus was assessed and compared with that of other NA inhibitors. We found that R-125489 bound to NA more tightly than did any other NA inhibitor tested. Our results indicate that CS-8958 is highly effective for the treatment and prophylaxis of infection with H5N1 influenza viruses, including oseltamivir-resistant mutants.

Vyšlo v časopise: Efficacy of the New Neuraminidase Inhibitor CS-8958 against H5N1 Influenza Viruses. PLoS Pathog 6(2): e32767. doi:10.1371/journal.ppat.1000786
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1000786

Souhrn

Zdroje

1. FioreAE

ShayDK

BroderK

IskanderJK

UyekiTM

2008 Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 57 1 60

2. SimonsenL

1999 The global impact of influenza on morbidity and mortality. Vaccine 17 Suppl 1 S3 10

3. YuenKY

ChanPK

PeirisM

TsangDN

QueTL

1998 Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 351 467 471

4. SubbaraoK

KlimovA

KatzJ

RegneryH

LimW

1998 Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279 393 396

5. ClaasEC

OsterhausAD

van BeekR

De JongJC

RimmelzwaanGF

1998 Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351 472 477

6. GerdilC

2003 The annual production cycle for influenza vaccine. Vaccine 21 1776 1779

7. DaviesWL

GrunertRR

HaffRF

McGahenJW

NeumayerEM

1964 Antiviral Activity of 1-Adamantanamine (Amantadine). Science 144 862 863

8. HaydenFG

2001 Perspectives on antiviral use during pandemic influenza. Philos Trans R Soc Lond B Biol Sci 356 1877 1884

9. BrightRA

MedinaMJ

XuX

Perez-OronozG

WallisTR

2005 Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366 1175 1181

10. BrightRA

ShayDK

ShuB

CoxNJ

KlimovAI

2006 Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. Jama 295 891 894

11. DawoodFS

JainS

FinelliL

ShawMW

LindstromS

2009 Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 360 2605 2615

12. CheungCL

RaynerJM

SmithGJ

WangP

NaiposposTS

2006 Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis 193 1626 1629

13. SchunemannHJ

HillSR

KakadM

BellamyR

UyekiTM

2007 WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 7 21 31

14. KisoM

MitamuraK

Sakai-TagawaY

ShiraishiK

KawakamiC

2004 Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364 759 765

15. WardP

SmallI

SmithJ

SuterP

DutkowskiR

2005 Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 55 Suppl 1 i5 i21

16. HatakeyamaS

SugayaN

ItoM

YamazakiM

IchikawaM

2007 Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. Jama 297 1435 1442

17. NicollA

CiancioB

KramarzP

2008 Observed oseltamivir resistance in seasonal influenza viruses in Europe interpretation and potential implications. Euro Surveill 13

18. TamuraD

MitamuraK

YamazakiM

FujinoM

NirasawaM

2009 Oseltamivir-resistant influenza a viruses circulating in Japan. J Clin Microbiol 47 1424 1427

19. de JongMD

TranTT

TruongHK

VoMH

SmithGJ

2005 Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353 2667 2672

20. LeQM

KisoM

SomeyaK

SakaiYT

NguyenTH

2005 Avian flu: isolation of drug-resistant H5N1 virus. Nature 437 1108

21. YamashitaM

TomozawaT

KakutaM

TokumitsuA

NasuH

2009 CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 53 186 192

22. ItohY

ShinyaK

KisoM

WatanabeT

SakodaY

2009 In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460 1021 1025

23. NeumannG

NodaT

KawaokaY

2009 Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459 931 939

24. LeMT

WertheimHF

NguyenHD

TaylorW

HoangPV

2008 Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam. PLoS ONE 3 e3339 doi:10.1371/journal.pone.0003339

25. TakanoR

NidomCA

KisoM

MuramotoY

YamadaS

2009 Phylogenetic characterization of H5N1 avian influenza viruses isolated in Indonesia from 2003–2007. Virology 390 13 21

26. HondaT

MasudaT

YoshidaS

AraiM

KanekoS

2002 Synthesis and anti-influenza virus activity of 7-O-alkylated derivatives related to zanamivir. Bioorg Med Chem Lett 12 1925 1928

27. HondaT

MasudaT

YoshidaS

AraiM

KobayashiY

2002 Synthesis and anti-influenza virus activity of 4-guanidino-7-substituted Neu5Ac2en derivatives. Bioorg Med Chem Lett 12 1921 1924

28. BabuYS

ChandP

BantiaS

KotianP

DehghaniA

2000 BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 43 3482 3486

29. HattaM

HattaY

KimJH

WatanabeS

ShinyaK

2007 Growth of H5N1 influenza A viruses in the upper respiratory tracts of mice. PLoS Pathog 3 e133 doi:10.1371/journal.ppat.0030133

30. NeumannG

WatanabeT

ItoH

WatanabeS

GotoH

1999 Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A 96 9345 9350

31. GubarevaLV

WebsterRG

HaydenFG

2001 Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother 45 3403 3408

32. BantiaS

ArnoldCS

ParkerCD

UpshawR

ChandP

2006 Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res 69 39 45

33. KaplanEL

MeierP

1958 Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 53 457 481

34. BantiaS

ParkerCD

AnanthSL

HornLL

AndriesK

2001 Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob Agents Chemother 45 1162 1167

35. SmeeDF

HuffmanJH

MorrisonAC

BarnardDL

SidwellRW

2001 Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother 45 743 748

36. YenHL

MontoAS

WebsterRG

GovorkovaEA

2005 Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 192 665 672

37. McKimm-BreschkinJL

SelleckPW

UsmanTB

JohnsonMA

2007 Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg Infect Dis 13 1354 1357